These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36828867)

  • 1. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN).
    Stegelmann F; Teichmann LL; Heidel FH; Crodel CC; Ernst T; Kreil S; Reiter A; Otten S; Schauer S; Körber RM; Kricheldorf K; Isfort S; Döhner H; Brümmendorf TH; Griesshammer M; Döhner K; Koschmieder S
    Leukemia; 2023 Apr; 37(4):924-928. PubMed ID: 36828867
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 3. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
    Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
    Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
    Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study.
    Langer C; Lengfelder E; Thiele J; Kvasnicka HM; Pahl HL; Beneke H; Schauer S; Gisslinger H; Griesshammer M
    Haematologica; 2005 Oct; 90(10):1333-8. PubMed ID: 16219569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
    Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
    Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
    Verger E; Cassinat B; Chauveau A; Dosquet C; Giraudier S; Schlageter MH; Ianotto JC; Yassin MA; Al-Dewik N; Carillo S; Legouffe E; Ugo V; Chomienne C; Kiladjian JJ
    Blood; 2015 Dec; 126(24):2585-91. PubMed ID: 26486786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia.
    Noel N; Michot JM; Besson C; Goujard C; Lambotte O
    Int J Hematol; 2013 Mar; 97(3):438-9. PubMed ID: 23400413
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
    Gowin K; Thapaliya P; Samuelson J; Harrison C; Radia D; Andreasson B; Mascarenhas J; Rambaldi A; Barbui T; Rea CJ; Camoriano J; Gentry A; Kiladjian JJ; O'Connell C; Mesa R
    Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
    Ianotto JC; Chauveau A; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; de Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Benbrahim O; Ugo V; Lippert E; Kiladjian JJ
    Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferon-alpha in the treatment of myeloproliferative diseases].
    Kissová J
    Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.
    Forsyth CJ; Chan WH; Grigg AP; Cook NC; Lane SW; Burbury KL; Perkins AC; Ross DM
    Intern Med J; 2019 Aug; 49(8):948-954. PubMed ID: 30411442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
    O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
    Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
    Beauverd Y; Radia D; Cargo C; Knapper S; Drummond M; Pillai A; Harrison C; Robinson S
    Haematologica; 2016 May; 101(5):e182-4. PubMed ID: 26819057
    [No Abstract]   [Full Text] [Related]  

  • 20. Essential thrombocythaemia treatment options: addressing patient-specific needs.
    Birgegård G
    Eur J Haematol Suppl; 2007 Oct; (68):27-31. PubMed ID: 17727563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.